Tau Technologies

Tau Technologies is a biotechnology company focused on the development of the Passive Neutralization (Tau PN) platform, a novel therapeutic approach for the treatment and prevention of viral and bacterial infections. The Tau PN technology utilizes engineered fusion proteins that act as molecular decoys, binding to conserved regions of pathogens to neutralize them before they can infect host cells. This platform is designed to provide immediate, instant immunity that is independent of the host's immune system, making it particularly valuable for immunocompromised individuals and as a rapid response to emerging variants. The company's current pipeline includes pre-clinical programs targeting SARS-CoV-2, influenza, respiratory syncytial virus (RSV), and biodefense threats such as anthrax. Tau Technologies operates as a multi-disciplinary entity, collaborating with the Vaccine and Immunotherapy Center at Massachusetts General Hospital to advance its life sciences portfolio.